Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
1 drug for “Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer”
Phase 3 1
- AZD9291ASTRAZENECA PLCLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.